Health Economics›Melanoma›Metastatic or unresectable disease

Metastatic or unresectable disease

Melanoma · 28 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 8 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Ipilimumab monotherapy Variant #01	—	R 786 153	84d	3.1 mo	11.5 mo	4	R 3 144 612 PFS proxy	5
Ipilimumab and Sargramostim Variant #01 Partial	—	R 786 153	84d	—	17.5 mo	4	R 3 144 612 PFS proxy	—
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	4.9 mo	32.7 mo	2	R 573 911 PFS proxy	7
Nivolumab-Ipilimumab Variant #01 Partial	—	R 235 846	21d	—	—	6	R 943 384 PFS proxy	1
Ipilimumab-Nivolumab Variant #01 Partial	—	R 235 846	21d	—	—	~4	~R 943 384 indirect	—
Ipilimumab and Nivolumab Variant #01 Partial	—	R 78 615	42d	~11.5 mo	~72.0 mo	~9	~R 707 538 PFS proxy · indirect	6
nab-Paclitaxel monotherapy Variant #01	—	R 16 043	28d	4.8 mo	—	2	R 32 087 PFS proxy	1
CVD, IL-2, IFN alfa-2b - sequential biochemotherapy Variant #01 Partial	—	R 8 684	21d	—	~118.8 mo	~6	~R 52 102 PFS proxy · indirect	1
CVD (Vindesine) Variant #01 Partial	—	R 4 936	21d	—	~12.0 mo	~4	~R 19 155 PFS proxy · indirect	—
Dacarbazine and Tamoxifen Variant #01	—	R 4 531	21d	—	11.0 mo	2	R 9 062 PFS proxy	—
BCG and Dacarbazine Variant #01 Partial	—	R 4 347	21d	—	—	~2	~R 8 695 indirect	—
BVD Variant #01 Partial	—	R 3 805	28d	—	—	~2	~R 7 609 indirect	—
Carboplatin and Dacarbazine Variant #01	—	R 3 679	28d	—	—	~3	~R 11 036 indirect	—
Cisplatin, Dacarbazine, Interferon alfa-2b Variant #01 Partial	—	R 3 491	28d	—	9.0 mo	4	R 13 964 PFS proxy	1
Temozolomide monotherapy Variant #02	—	R 3 434	14d	~1.6 mo	—	~27	~R 92 712 PFS proxy · indirect	1
BHD Variant #01 Partial	—	R 3 025	28d	—	—	~3	~R 9 075 indirect	—
Docetaxel monotherapy Variant #02	—	R 2 921	28d	~3.2 mo	~9.5 mo	~8	~R 23 372 PFS proxy · indirect	83
CDB Variant #01 Partial	—	R 2 760	42d	—	—	~6	~R 16 559 indirect	—
Dacarbazine monotherapy Variant #01	—	R 2 608	21d	1.5 mo	9.6 mo	2	R 5 217 PFS proxy	6
Cisplatin, Dacarbazine, Tamoxifen Variant #01	—	R 2 332	21d	—	—	~2	~R 4 512 indirect	—
Dacarbazine and Interferon alfa-2a Variant #01 Partial	—	R 2 319	21d	—	11.0 mo	2	R 4 637 PFS proxy	—
Paclitaxel monotherapy Variant #02	—	R 734	28d	1.7 mo	9.4 mo	7	R 5 141 PFS proxy	4
High-dose Interleukin-2 Variant #01 Partial	—	—	84d	—	—	~4	—	—
Nivolumab monotherapy Variant #01 Partial	—	—	14d	~4.6 mo	~34.1 mo	~2	—	10
BCG vaccine monotherapy Variant #01 Partial	—	—	30d	—	38.6 mo	1	—	1
Sargramostim monotherapy Variant #01 Partial	—	—	28d	—	—	~2	—	—
Placebo Partial	—	—	—	—	7.4 mo	—	—	1
Low-dose Interleukin-2 Variant #01 Partial	—	—	42d	—	—	~2	—	—

28 of 28 regimens shown